An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 1-13

  Garcia, Jacqueline S ^a   Jain, Nitin ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 aza deoxycytidine; 5 azacitidine; Decitabine; Myelodysplastic syndromes

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; CARDIOVASCULAR DISEASE; CHILL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEADACHE; HEARING IMPAIRMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; PNEUMONIA; PYREXIA IDIOPATHICA; RASH; REVIEW; SLEEP DISORDER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 77953393113     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114:937-951.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872-1885.
3. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109:1536-1542.
4. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83:358-368.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
6. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol. 2005;84 Suppl 1:9-17.
7. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15:3938-3946.
8. Gore SD, Jones C, Kirkpatrick P. Decitabine. Nat Rev Drug Discov. 2006;5:891-892.
9. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
10. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8-13.
11. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67:6400-6408.
12. Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007;48:1676-1695.
13. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884-3891.
14. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361-6369.
15. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114:3448-3458.
16. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
17. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
18. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res. 1981;5:453-462.
19. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30:277-286.
20. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia. 1993;7 Suppl 1:49-50.
21. Zagonel V, Lo Re G, Marotta G, et al. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993;7 Suppl 1:30-35.
22. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
23. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109:1133-1137.
24. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase iii study (06011) of the EORTC Leukemia and German MDS Study Groups. 50th American Society of Hematology Annual Meeting. San Francisco, California: Blood. 2008:226.
25. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
26. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109:265-273.
27. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115:5746-5751.
28. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27:3842-3848.
29. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006;106:1744-1750.
30. Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6:902-926.
31. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004; 45:1311-1318.
32. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11:1-5.
33. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008; 32:587-591.
34. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109:713-717.
35. Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol. 2006;19:519-533.
36. Kroger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology Am Soc Hematol Educ Program. 2008:60-67.
37. Lubbert M, Hartmut B, Ruter B, Mertelsmann R, Finke J. Non-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients. 48th American Society of Hematology Annual Meeting. Orlando, FL: Blood. 2006:5257.
38. De Padua S, de Lima M, Kantarjian H, et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2'-deoxy-5 azacytidine for patients with myelodysplastic syndrome. 49th American Society of Hematology Annual Meeting. Atlanta, GA: Blood. 2007:1468.
39. Czibere A, Graef T JL, et al. 5-Azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell Transplantation. 48th American Society of Hematology Annual Meeting. Orlando, FL: Blood. 2006:5341.
40. de Lima M, Padua L, Giralt S, et al. A dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS. 49th American Society of Hematology Annual Meeting: Blood. 2007:3012.
41. De Padua Silva L, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009;43:839-843.
42. Jain N, Mattiuzzi GN, Cortes J, et al. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodys-plastic syndrome receiving frontline "targeted therapy". 49th American Society of Hematology Annual Meeting. Atlanta, Georgia: Blood. 2007:2858.
43. Chen CC, Gau JP, You JY, et al. Decitabine-induced effusions. Leuk Res. 2009;33:e150-e151.
44. Vasu TS, Cavallazzi R, Hirani A, Marik PE. A 64-year-old male with fever and persistent lung infiltrate. Respir Care. 2009;54:1263-1265.
45. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
46. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49:690-695.
47. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis. Haematologica. 2009.
48. Kumar A, List AF, Mhaskar R, Djulbegovic B. Efficacy of hypo-methylating agents in the treatment of myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. 50th American Society of Hematology Annual Meeting. San Francisco, California: Blood. 2008:3632.
49. Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2009.
50. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
51. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103-107.
52. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141-149.
53. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
54. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005;29:739-748.
55. Ravandi F, Faderl S, Thomas D, et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. 49th American Society of Hematology Annual Meeting. New Orleans, Louisiana: Blood. 2007:897.